Cargando…

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

BACKGROUND: Most thyroid cancers of follicular origin have a favorable outcome. Only a small percentage of patients will develop metastatic disease, some of which will become radioiodine refractory (RAI-R). Important challenges to ensure the best therapeutic outcomes include proper, timely, and appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capdevila, Jaume, Deandreis, Desiree’, Durante, Cosimo, Leboulleux, Sophie, Luster, Markus, Netea-Maier, Romana, Newbold, Kate, Singer, Susanne, Sykiotis, Gerasimos P, Bartes, Beate, Farnell, Kate, Locati, Laura Deborah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448584/ https://www.ncbi.nlm.nih.gov/pubmed/37429326 http://dx.doi.org/10.1530/ETJ-23-0068

Ejemplares similares

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
por: Taylor, Matthew H., et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Brose, Marcia S, et al.
Publicado: (2021)

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
por: Pacini, Furio, et al.
Publicado: (2021)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
por: Wadsley, Jon, et al.
Publicado: (2023)

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
por: Cabanillas, Maria E., et al.
Publicado: (2015)

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma
por: Peng, Chunying, et al.
Publicado: (2023)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma
por: Zheng, Adi, et al.
Publicado: (2019)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review
por: Sheu, Nai-Wei, et al.
Publicado: (2019)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Zheng, Xiangqian, et al.
Publicado: (2021)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
por: Martínez‐Trufero, Javier
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022)

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
por: Brown, Sarah R., et al.
Publicado: (2019)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
por: Jimenez‐Fonseca, Paula
Publicado: (2022)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials
por: Yan, Zhipeng, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
por: Navarro‐Gonzalez, Elena
Publicado: (2022)

Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
por: Taprogge, Jan, et al.
Publicado: (2023)

Keap1/Nrf2 Signaling Pathway
por: Sykiotis, Gerasimos P.
Publicado: (2021)

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
por: Rendl, G., et al.
Publicado: (2020)

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
por: Elisei, Rossella, et al.
Publicado: (2023)

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
por: Robinson, Bruce, et al.
Publicado: (2016)

The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
por: Taprogge, Jan, et al.
Publicado: (2023)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v43une6ujjg34u6h6e6q5nsfb0